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Abstract
BACKGROUND: Recent insights provide support for the treatment of cancer
during pregnancy, a coincidence that poses both mother and fetus at risk.
Our aim was to critically review studies on the physiologic variations during
pregnancy, the most common tumor markers used in diagnosis and follow-up
of gynecological cancers. METHODS: We conducted a systematic review of
six tumor markers during normal pregnancy: carbohydrate antigen (CA) 15-3
(breast cancer); squamous cell carcinoma antigen (cervical cancer); and CA 125,
anti-Müllerian hormone, inhibin B and lactate dehydrogenase (ovarian cancer).
RESULTS: For CA 15-3, 3.3% to 20.0% of all measurements were above the cut-
off (maximum 56 U/mL in the third trimester). Squamous cell carcinoma antigen
values were above cut-off in 3.1% and 10.5% of the measurements (maximum
4.3 µg/L in the third trimester). Up to 35% of CA 125 levels were above cut-off:
levels were highest in the first trimester, with a maximum value up to 550 U/mL.
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Abstract
Background: Recent insights provide support for the treatment of cancer during pregnancy, a coincidence that
poses both mother and fetus at risk. Our aim was to critically review studies on the physiologic variations during
pregnancy, the most common tumor markers used in diagnosis and follow-up of gynecological cancers.
Methods: We conducted a systematic review of six tumor markers during normal pregnancy: carbohydrate antigen
(CA) 15-3 (breast cancer); squamous cell carcinoma antigen (cervical cancer); and CA 125, anti-Müllerian hormone,
inhibin B and lactate dehydrogenase (ovarian cancer).
Results: For CA 15-3, 3.3% to 20.0% of all measurements were above the cut-off (maximum 56 U/mL in the third
trimester). Squamous cell carcinoma antigen values were above cut-off in 3.1% and 10.5% of the measurements
(maximum 4.3 µg/L in the third trimester). Up to 35% of CA 125 levels were above cut-off: levels were highest in
the first trimester, with a maximum value up to 550 U/mL. Inhibin B, anti-Müllerian hormone and lactate
dehydrogenase levels were not elevated in maternal serum during normal pregnancy.
Conclusion: During normal pregnancy, tumor markers including CA 15.3, squamous cell carcinoma antigen and CA
125 can be elevated; inhibin B, anti-Müllerian hormone and lactate dehydrogenase levels remain below normal
cut-off values. Knowledge of physiological variations during pregnancy can be clinically important when managing
gynecological cancers in pregnant patients.
Keywords: anti-Müllerian hormone, CA 125; CA 15-3, cancer, human epididymis secretory protein 4 (HE4), inhibin
B, lactate dehydrogenase, pregnancy, squamous-cell carcinoma antigen tumor markers
Background
Tumor markers are biochemical substances found in the
presence of cancer and produced either by the tumor
itself or in response to (para)neoplastic conditions, such
as inflammation. Tumor markers can be found in a vari-
ety of bodily fluids and tissues and include hormones and
several subgroups of (glyco)proteins, such as oncofetal
antigens (which are normally expressed during fetal life),
enzymes and receptors. They are used for diagnosis,
assessment of therapeutic efficacy, and detecting recur-
rence during follow-up. The most limiting factor in the
clinical use of tumor markers is the lack of sensitivity and
specificity because the majority of markers are tumor-
associated rather than tumor-specific; elevated levels can
occur in different types of malignancies as well as in
benign and physiological conditions such as pregnancy
[1]. Moreover, early diagnosis and treatment of recur-
rences that are solely detected by the use of tumor mar-
ker alone has not shown survival benefit [2].
It is estimated that one in 1,000 to 2,000 pregnant
women are diagnosed with an intercurrent malignancy,
at an average age of 33 years [3]. Moreover, a slowly ris-
ing incidence rate has been observed since the 1960s [4].
Breast cancer, hematological malignancies and cervical
cancer are the most commonly encountered malignan-
cies during pregnancy [3]. Pregnancy after oncologic
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treatment is also becoming more common, mainly due to
advances in fertility-sparing treatment and improved
prognosis [5]. Diagnosis and treatment of these two types
of patients cannot always be extrapolated from the non-
pregnant patient; this is also the case when interpreting
tumor markers during pregnancy. Unawareness of preg-
nancy-related physiologic elevations of tumor markers
may lead to the search for metastatic disease, using
extensive and unnecessary diagnostic examinations that
are costly and uncomfortable, and also expose the fetus
to avoidable radiation.
At present, the number of studies conducted on serum
tumor markers during pregnancy is limited. Our goal is to
review existing publications on this topic, and also to pro-
vide an easily accessible table of reference values during
pregnancy for the most common tumor markers used in
cases of gynecological malignancies.
Methods
We focused on six tumor markers that are well-estab-
lished in gynecological cancers and are used for breast
cancer (carbohydrate antigen (CA) 15-3), cervical squa-
mous cell cancer (squamous cell carcinoma antigen
(SCC)), and ovarian cancer (CA 125 for epithelial ovarian
tumors, inhibin B and anti-Müllerian hormone (AMH)
for sex cord-stromal tumors, and lactate dehydrogenase
(LDH) for germ cell tumors). We conducted a systematic
literature search in MEDLINE to identify relevant publi-
cations from 1 January 1980 to 31 September 2011 in the
English language. Additional publications were identified
from the reference lists of relevant articles (Figure 1).
The systematic search was conducted using the following
medical subject headings (MeSH) terms, words and com-
binations of words: pregnancy AND CA 15-3, squamous-
cell carcinoma antigen, CA 125, inhibin B, anti-Müllerian
hormone, lactate dehydrogenase. Two investigators (SH
and AL) independently identified potentially relevant
articles using the title and the abstract. Eligibility criteria
were as follows: firstly, when the maternal serum tumor
marker was studied in healthy pregnant women without
medical or obstetric confounding conditions, and sec-
ondly, if the gestational age was reported by trimester.
For inhibin, we excluded older publications that used
assays unable to differentiate between dimeric forms and
thus were nondiscriminatory between inhibin A and B.
Due to the diverse study designs and conditions and use
of different assay methods with different intra-and inter-
assay coefficients of variation, a meta-analysis was not
possible.
a-fetoprotein and the b subunit of human chorionic
gonadotropin are both substances that are abundantly
present during gestation and have been extensively
investigated. Reference values during pregnancy are
available in most laboratories, hence we did not include
these two markers in our review.
Results
The database search provided 1,786 articles for the six
tumor markers combined. After an initial review of the
title and abstract, 54 articles appeared to be relevant and
were retrieved to be reviewed in full. Twenty-six studies
met our inclusion criteria and were included in the
review. Table 1 provides a short summary of the general
characteristics of the tumor markers (clinical use, mole-
cular weight and production site). Definitions on the
three trimesters of pregnancy varied between publica-
tions. The first trimester was defined as the period
between the beginning of pregnancy up to 12 to 14
weeks’ gestation; the second trimester was defined as the
period from the end of the first trimester up to 24 to 28
weeks’ gestation, after which began the third trimester
until delivery. For each tumor marker, data were
extracted from as many studies as possible. These ranges
were combined to establish a normal reference range per
trimester (Table 2). Cut-off values used in clinical oncol-
ogy for non-pregnant adults are as stated in the publica-
tions and also listed in Table 2.
Breast cancer
Cancer antigen 15-3
As illustrated in Table 3, CA 15-3 values were described in
six publications [6-11], of which two (n = 12 and n = 30)
had a longitudinal design [7,11]. Although values largely
remained below the cut-off, a significantly increased level
was observed during pregnancy in five of the six studies,
with the highest levels occurring in the third trimester. In
three of the four most recent studies, between 3.3% and
20% of all measurements were found to be above the cut-
off value [8-11]. The highest reported CA 15-3 value was
56 U/mL in the third trimester [10].
Cervical cancer
Squamous cell carcinoma antigen
Physiological circulating levels of SCC throughout gesta-
tion have only been reported in two studies to date
[6,7]. In 1989, Touitou et al. [6] published a cross-sec-
tional study of maternal serum SCC including 32, 32,
and 36 women in each of the three pregnancy trime-
sters, respectively. The observed SCC levels were
0.77 µg/L ± 0.60 (mean ± SD), 1.25 µg/L ± 0.37 and
1.10 µg/l ± 0.56 for the first, second and third trimester,
respectively. The SCC levels were significantly higher in
the second and third trimesters when compared with
the first trimester. The mean concentrations stayed well
within the normal range whilst 3.1% of participants had
levels exceeding the cut-off value (exact cut-off not
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stated) [6]. In 1998, Schlageter et al. [7] obtained four to
nine serum samples from each of 12 healthy pregnant
women serially throughout gestation. They also observed
higher levels in the third trimester, although mean levels
remained below the cut-off throughout the entire preg-
nancy. SCC concentrations were found to exceed the
cut-off value of 1.6 µg/L in 10.5% of samples (range 0.1
to 4.3 µg/L).
Epithelial ovarian cancer
Cancer antigen 125
Although CA 125 is the most studied tumor marker in
pregnancy, the different reports are contradictory. We
found ten publications [7,10-18], of which four had a long-
itudinal study design [7,11,15,18]; an overview is shown in
Table 4. Elevated levels were found in all ten studies, in up
to 35% of the measurements. CA 125 levels were uni-
formly reported to be highest in the first trimester, with a
maximum value up to 550 U/mL [13]. For the second and
third trimester, mean maternal CA 125 values were found
generally below the cut-off value and remaining below this
level until delivery. Nonetheless, four studies found ele-
vated levels up to 73 U/mL in the second trimester
[7,10,13,17], and eight studies found elevated levels in the
third trimester [7,10,11,13-17], with a maximum level of
2,419.7 U/mL.
Records identified through 
database search  
(n = 1504) 
Abstracts screened 
(n = 268) 
Full-text articles assessed for 
eligibility 
(n = 70) 
Studies included in current 
review 
(n = 26) 
Records excluded (n = 198) 
-Tumor markers measured in other tissues 
(human amniotic fluid, fetal membranes, 
fetal tissue, endometrium, myometrium, 
decidua, trofoblast).  
Full-text articles excluded (n = 44) 
-Serum tumor markers measured in case of 
obstetrical complications (e.g. miscarriage, 
ectopic pregnancy, pre-eclampsia, 
intrauterine growth restriction, high risk 
pregnancy, chromosomal abnormalities). 
-Gestational age not reported. 
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Figure 1 Methodology for literature review.
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Sex cord-stromal tumor
Inhibin B
To date, two studies have measured inhibin B levels in
healthy pregnant women longitudinally during gestation.
Petraglia et al. [19] followed 13 pregnant women: mean ±
SD values showed that serum inhibin B levels during the
first (27.50 ± 2.72 ng/L) and second (38.00 ± 9.06 ng/L)
trimester were significantly lower than at the third trime-
ster (115.5 ± 28.19 ng/L; P <0.001). Values at term were
significantly higher than in their control group of non-
pregnant women during the early follicular and early luteal
phases of the menstrual cycle (P <0.01). Fowler et al. [20]
measured inhibin B in six healthy pregnant women and
found that concentrations of inhibin B fell to undetectable
concentrations (<12 ng/L) during the first half of preg-
nancy and only increased slightly in the second half to a
maximum concentration of 25 ng/L, which was still well
below the normal cut-off level for the non-pregnant pre-
menopausal adult female (and 200-fold lower than inhibin
A levels). Wallace et al. [21] found undetectable inhibin B
levels in maternal serum from 807 pregnancies with 10 to
20 weeks’ gestational age.
Table 1 Tumor marker characteristics.
Tumor
marker
Clinical use in
gynecological
oncology
Production site in normal adult Production site during
pregnancy
Molecular
weight
Carbohydrate
antigen 15-3
Breast cancer Glandular epithelia Uncertain
(maternal mammary
gland epithelium?
placenta?)
290 kDa
Squamous cell
carcinoma
antigen
Cervical squamous
cell cancer
Squamous epithelia (both benign and malignant) Uncertain
(fetus?)
42 kDa
Carbohydrate
antigen 125
Non-mucinous
ovarian cancer
Structures derived from the celomic epithelium (such as
endocervix, endometrium, and fallopian tube) and in tissues
developed from mesothelial cells (such as pleura, pericardium
and peritoneum)
Decidua and amnion
cells
200 to 250 kDa
Inhibin B Granulosa cell
tumors
(some (mucinous)
epithelial ovarian
tumors)
Granulosa and theca cells (member of the transforming growth
factor-b family)
Granulosa and theca cells Monomer
15 kDa,
homodimer
25 kDa
Anti-Müllerian
hormone
Granulosa cell
tumors
Granulosa cells of ovarian follicles (member of the transforming
growth factor-b family)
Sertoli cells of male fetus,
for regression of
Müllerian ducts
140 kDa
Lactate
dehydrogenase
Germ cell tumors Cell cytoplasm Cell cytoplasm 140 kDa
Table 2 Overview of ranges during pregnancy per tumor marker.
Normal oncologic cut-off values in non-
pregnant women
Trimester 1a Trimester 2 Trimester 3 References
Carbohydrate antigen 15-3b <30 U/mL 5.0 to 39.3 1.0 to 40 7.0 to 56 [7,11,51,52]
1.3 to 19.5 4.0 to 24.4 7.0 to 27 [6,7]
Squamous cell carcinoma
antigen
<2 µg/L 0.3 to 2.9 0.1 to 2.2 0.6 to 4.3 [7]
0 to 1.97 0.51 to 1.99 0 to 2.22 [6]
Carbohydrate antigen 125 <39 U/mL 3.7 to 550 1 to 166.6 6.1 to 2,419.7 [7,10,11,13,14,17,18]
0 to 215.1 0 to 308 0 to 56.3 [15,16]
Inhibin B ng/mL NA NA NA NA
22.06 to
32.94
19.88 to
56.12
58.62 to
171.38
[19]
Anti-Müllerian hormone ng/mL 0.2 to 9.3 0.5 to 4.0 0.2 to 3 [22,23]
NA NA NA NA
Lactate dehydrogenase <221 U/L 78 to 433 80 to 447 82 to 524 [25-28]
NA NA NA NA
NA, not applicable. aThe definition of first, second and third trimester is the one used in the study and differs from one study to the other; b for each parameter
the non-pregnant reference value is the mean of all studies, whereas lowest and highest ranges and 2.5 to 97.5 percentiles in the three pregnancy trimesters are
presented in the first and the second row, respectively.
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Table 3 Overview of selected studies on carbohydrate antigen 15-3 levels during normal pregnancy.
Author/year of
publication
Study
design
Laboratory technique Number of patients Cut-off
value
Trimester
1
Trimester 2 Trimester 3 Conclusion
1 Touitou 1989 [6] cross-
sectional
IRMA, CIS-Bio International, Gif-
Sur-Yvette, France
T1 n = 32; T2 n = 32;
T3 n = 36
<25 11.1 ± 4.2
mean ± SD
14.2 ± 5.1 17.0 ± 5.0 None above cut-off value
2 Schlageter 1998
[7]
longitudinal ELSA-CA 15-3 (CIS-Bio
International), Gif-Sur-Yvette,
France
n = 12 <30 9.3 ± 4.0
(mean ±
SD)
5 to 15
(range)
14.1 ± 4.1
10 to 22.8
16.5 ± 4.1
8.8 to 24.2
None above cut-off value
3 Botsis 1999 [8] cross-
sectional
EIA, Tumor markers CA 153,
Abbott AXSYM system, Abbott
Park, Il, USA
T1 n = 20; T2 n = 29;
T3 n = 26
<33 18.0
(median)
14 to 30
(range)
20
1.0 to 34
22
12 to 41
5%, 10% and 20% above cut-off value, in
the 3 trimesters respectively
4 Cheli 1999 [9] cross-
sectional
Bayer Immuno 1 CA 15-3 assay,
Tarrytown, New York, USA)
T1 n = 32; T2 n = 5;
T3 n = 53
<35 16.76
(mean)
- 20.78 3.3% above cut-off value
5 Bon 2001 [10] cross-
sectional
Enzymun-Test CA 15-3
(Boehringer, Mannheim,
Germany)
T1 n = 127; T2 n =
192; T3 n = 47
Not
stated
14.0
(median)
5.0 to 32
(range)
15.0
6.0 to 40
26.0
9 to 56
Raised above cut-off value, percentage not
stated
6 Ercan 2011 [11] longitudinal Modular Analytics E 170 Module
(Roche diagnostics), Basel,
Switserland.
n = 30 <25 17.5
(median)
7.6 to 39.3
(range)
19.7
10.4 to 39
18.3
7 to 38.6
16% above cut-off value
SD, standard deviation; T, trimester.
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Table 4 Overview of selected studies on carbohydrate antigen 125 levels during normal pregnancy.
Author/year of
publication
Study design Laboratory technique Number of
patients
Cut-off
value
(U/mL)
Trimester 1 Trimester
2
Trimester
3
Conclusion
1 Niloff 1984 [12] cross-sectional 125I-labeled OC125 N = 101 <65 >65 in 16% < 65 <65 T1: 16% above cut-off value
2 Haga 1986 [13] cross-sectional Centocore Inc., Malvern, PA, USA T1 n = 29; T2 n =
21; T3 n = 21
<35 85 ± 101
(mean ± SD)
18 to 550
(range)
20 ± 10
10 to 54
25 ± 27
<8 to 140
Raised above cut-off value,
percentage not stated
3 Jacobs 1988 [14] cross-sectional Abbott Laboratories, Chicago, IL, USA T1 n = 11; T2 n = 7;
T3 n = 8
<35 53.6 (median)
15.6 to 268.3
(range)
18.5
12.0 to
25.1
19.2
16.8 to
43.8
35% above cut-off value
4 Kobayashi 1989
[15]
both cross-sectional
and longitudinal
ORIS Industry, Censaclay, France n = 122 <35 71.7 ± 71.1
(mean ± SD)
19.1 ± 7.0 28.1 ±14.1 Raised above cut-off value,
percentage not stated
5 Touitou 1989
[16]
cross-sectional IRMA, CIS-Bio International, Gif-Sur-Yvette,
France
T1 n = 32; T2 n =
32; T3 n= 36
<35 23.7± 13.9
(mean ± SD)
14.8 ± 8.0 22.1 ±
17.1
8% above cut-off value
6 Kenemans 1992
[17]
cross-sectional Enzymun CA 125 (Boehringer, Mannheim,
Germany)
T1 n = 26; T2 n =
20; T3 n = 145
<35 24.4 ± 13.3
(mean ± SD)
54.6
(maximum
range)
38.1 ±
47.4
166.6
74.7 ±
273.3
2,419.7
T1: 19% above cut-off value
T2: 15% above cut-off value
T3: 20% above cut-off value
7 Schlageter 1998
[7]
longitudinal ELSA-CA 125 (CIS Bio International-Bio
International, Gif-Sur-Yvette, France
n = 12 <40 18.7 ± 14.0
(mean ± SD)
6.1 to 41.5
(range)
19.9 ±
12.5
6.5 to 54.3
22.3 ±
13.1
6.1 to 51.3
Raised above cut-off value,
percentage not stated
8 Spitzer 1998 [18] longitudinal Centocore Inc., Diagnostic division, Malvern,
PA, USA
n = 20 <35 33.1 (median)
3.7 to 251.2
(range)
<35 <35 Raised above cut-off value,
percentage not stated
9 Bon 2001 [10] cross-sectional Enzymun-Test CA 125 (Boehringer,
Mannheim, Germany)
T1 n = 127; T2 n =
192; T3 n = 47
Not
stated
23 (median)
4 to 108
(range)
14
1 to 73
21
8 to 144
Raised above cut-off value,
percentage not stated
10 Ercan 2012 [11] longitudinal Modular Analytics E 170 Module (Roche
diagnostics, Basel, Switserland
n = 30 <35 19.0 (median)
4.9 to 61
(range)
15.6
4.7 to 32.1
19.6
9.8 to 41.2
4.4% above cut-off value
CA, carbohydrate antigen; ELISA, enzyme-linked immunosorbent assay; IRMA, immunoradiometric assay; SD: standard deviation; T, trimester;
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Anti-Müllerian hormone
AMH levels during the three trimesters of pregnancy
were published in two articles. La Marca et al. [22] con-
ducted a cross-sectional study in 27, 21 and 13 women
in the three trimesters respectively, and found that
serum AMH values were similar to those of non-preg-
nant women in the follicular phase, and tended to
decrease with progression of the pregnancy. These find-
ings were confirmed by Nelson et al. [23] in a prospec-
tive longitudinal cohort of 60 pregnant women, they
also found normal levels during the first trimester, with
a significant decline during the second and third trime-
ster. Lutterodt et al. [24] compared first trimester AMH
maternal serum levels in relation to the fetal sex (deter-
mined by X-Y polymerase chain reaction of fetal tissue
after elective termination of pregnancy), and no correla-
tion was found.
Germ cell tumor
Lactate dehydrogenase
During normal uncomplicated pregnancy, reported LDH
values all remained below the normal cut-off values
[25-28].
Discussion
Although tumor markers are very commonly used in
clinical practice, their relevance and reliability is fre-
quently debated. Tumor markers mainly have a suppor-
tive function, even for the routine care of non-pregnant
patients. The role of tumor markers is limited in cases of
cancer during pregnancy, or pregnancy after cancer,
mainly due to their low specificity rate. Elevations are not
always correlated with the presence of malignancy but
are more often associated with normal physiologic
changes of pregnancy. Moreover, obstetrical complica-
tions can induce even more variations. For example, ele-
vated CA 125 has been associated with imminent
miscarriage [29], and LDH is known to increase in cases
of severe preeclampsia and HELLP (hemolysis, elevated
liver function tests, low platelets) [26]. Physicians and
midwives caring for pregnant women are well aware that
the reference ranges of various laboratory values differ
during pregnancy [27,30], and this should also be the
case with tumor markers in pregnancy (Table 1). Here,
we summarize and explain the physiology of elevated
levels during pregnancy for CA 15.3, SCC and CA 125.
Inhibin-B, AMH and LDH are not elevated during nor-
mal pregnancy.
CA 15-3 is a well-characterized immunoassay that
allows the detection of the mucin (MUC)-1 antigen.
MUC-1 is part of the family of membrane-bound mucins,
large glycoproteins, and their expression is frequently ele-
vated in breast cancer cells. Elevated levels can be found
in the serum of over 70% of patients with advanced
breast cancer [31]. Conflicting data on the possible feto-
placental origin of CA 15-3 are reported. CA 15-3 con-
centrations in amniotic fluid and/or umbilical cord blood
were analyzed and remained very low throughout preg-
nancy [32-34]; the authors concluded that the combina-
tion of an elevated maternal CA 15-3 and low levels in
amniotic fluid and umbilical cord blood indicate that the
antigen is not produced by the fetus, placenta or decidual
tissue, and therefore, could not be considered as an onco-
fetal antigen [32-35]. However, MUC-1 has been detected
in trophoblastic tissue even very early in pregnancy; pla-
cental expression increases as the pregnancy progresses
and it is highly expressed throughout the third trimester
[36,37]. Several authors have hypothesized that CA 15-3
elevations in maternal serum may result from the prolif-
eration of maternal mammary gland epithelium late in
pregnancy, with enhanced secretion of mucin, as opposed
to placental transfer of the mucin [9,10,35]. Botsis et al.
[8], and also Ercan et al. [11], asserted that CA 15-3 is
independent of gestation and remains a reliable tumor
marker for breast cancer during pregnancy. This state-
ment is not in accordance with most other studies as
found in this review. Although the reported values during
pregnancy are only moderately elevated, we believe that
caution is warranted, and a higher cut-off value would
facilitate interpretation during pregnancy.
Elevated SCC serum levels are found in between 57%
and 70% of women with a primary squamous cell carci-
noma of the cervix. Elevated levels are also found in
between 24% and 53% of patients with squamous cell car-
cinomas of the head and neck, esophagus, and lung, and
also in between 8% and 42% of patients with adenocarci-
nomas of the ovary and uterus [38]. SCC is probably a
marker of cellular differentiation for squamous cells, as
the incidence of elevated serum levels is higher in women
with grade 1 (78%) and grade 2 (67%) carcinomas than in
those with grade 3 tumors (38% )[38]. Sarandakou et al.
sampled maternal serum, umbilical cord blood and amnio-
tic fluid during delivery of 56 full-termed pregnancies [39];
they found a high incidence of SCC levels above the cut-
off value of ≤2.5 µg/L (30% in maternal serum and 75% in
umbilical cord blood). The levels found in amniotic fluid
were extremely high (median 710 µg/L; range 30 to 7,692
µg/L), which led the authors to conclude that SCC is an
oncofetal antigen [39]. The analysis of in vitro culture of
amnion cells and amniotic membranes revealed no accu-
mulation of SCC in the supernatant, and no mRNA
expression of SCC was found in the amnion, the cord or
the placenta using a northern blot with a cDNA probe of
SCC [40]. Therefore, it is more likely that the fetus, and
not the placenta, is the origin of SCC found in amniotic
fluid, but this remains to be confirmed.
CA 125 is used for monitoring non-mucinous epithe-
lial ovarian cancer [7,41]. Of patients with ovarian
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carcinoma, 82% have CA 125 levels >35 U/mL, com-
pared with 1% of apparently healthy non-pregnant indi-
viduals. During pregnancy, CA 125 is present in
relatively high concentrations in decidual cells, amniotic
fluid and amnion cells, and significantly lower levels are
found in umbilical cord blood, suggesting that decidua
and amnion cells (and not the fetus) produce and
secrete CA 125 into the amniotic fluid [39,41,42]. Inter-
estingly, the molecular weight of CA 125 identified in
pregnancy was significantly higher than that observed in
ovarian cancer, suggesting a different production and/or
metabolism of CA 125 glycoprotein for different tissues
[35]. The large molecular weight of CA 125 in the feto-
placental unit prevents the passage of the antigen
through the basal membranes. Therefore, a large differ-
ence exists between amniotic fluid and maternal serum
concentrations of CA 125; disruption of the basal mem-
branes can cause a higher permeability from the fetopla-
cental unit into the maternal circulation [39]. Higher
maternal serum CA 125 levels in the first trimester can
be explained by the process of trophoblast invasion in
the decidua during placentation. Higher levels in the
third trimester, and more particularly in the puerperium,
can be caused by detachment of the placenta from the
uterus, during which time decidual CA 125 might reach
the maternal circulation [10].
In persisting adnexal masses during pregnancy, expert
ultrasonographic assessment plays a pivotal role in esti-
mating the risk of malignancy, and planning conservative
management for an adnexal mass that is probably benign
versus surgical treatment during pregnancy for an
adnexal mass that has malignant characteristics [43,44].
Ovarian cancer during pregnancy is very rare and has an
estimated incidence of 1 in 12,000 to 47,000 pregnancies
[43]. When uncertainty remains towards the type of
adnexal mass, despite expert evaluation, tumor markers
might be important to help formulate the differential
diagnosis. From the data presented, it is clear that the
usefulness of CA 125 in pregnant women must be care-
fully considered, as it is evident that maternal serum CA
125 concentrations are influenced by pregnancy, espe-
cially during the first trimester. Thus, an adjusted cut-off
level should be established in order to interpret CA 125
levels in pregnant patients [35]. Inhibin B and AMH are
both serum markers for granulosa cell tumors. Granulosa
cell tumors represent about 5% of all primary ovarian
neoplasms, and the juvenile type has a higher incidence
in children and young women. Currently, there is no evi-
dence-based preference to use inhibin B or AMH as
tumor marker in the non-pregnant patient [45]. During
pregnancy, an apparent increase in inhibin B immunor-
eactivity may reflect some cross-reaction with inhibin A.
Consequently, it is to be expected that AMH measure-
ments are more reliable during pregnancy than inhibin B.
Risk of bias
We aimed to minimize risk of bias of individual studies
by excluding all studies reporting tumor markers mea-
sured in pregnancies with pathology (for example, mis-
carriage, intrauterine growth restriction, preeclampsia,
aneuploidy) and/or without specification of gestational
age. Publication bias and selective reporting within stu-
dies is not expected for this research area.
Limitations of the present review and aims for future
research
There is no consensus on the clinical benefit of tumor
markers and staging procedures. As a result, their practi-
cal use differs significantly among centers. Despite this,
tumor markers are frequently used in clinical practice.
When measured in the pregnant patient, the pregnancy-
related physiologic alterations render the interpretation
of tumor marker values more difficult. Therefore, we
aimed to provide a better knowledge of tumor marker
values during pregnancy. The available literature remains
inconclusive for several reasons. The majority of studies
were cross-sectional and used small cohorts, which may
have led to underpowered conclusions. Comparability of
study results is further complicated by the different defi-
nitions used for the three trimesters of pregnancy and,
even more important, by the various types of assays with
different intra-and inter-assay coefficients of variation
and corresponding different degrees of precision, which
were not always mentioned. Confidence intervals and
standard deviations were not systematically stated, hence,
outliers could not always be excluded. Normal values for
pregnant women are still not well established. A longitu-
dinal prospective study with sufficient participants to
correct for interpatient heterogeneity would be more sui-
table to define the 2.5th and 97.5th percentiles for the dif-
ferent tumor markers during pregnancy [1].
Human epididymis secretory protein 4 (HE4, also
known as WFDC2) is a new marker for epithelial ovarian
carcinoma [46]. HE4 was first proposed as a serum tumor
marker for ovarian cancer in 2003 [47]. So far, its value as
an additional marker alongside CA 125 is still under
debate [48,49]. Interestingly, HE4 has an increased perfor-
mance in the premenopausal group, mainly because,
unlike CA 125, it is not overexpressed in cases of endome-
triosis [50]. The expression of HE4 during normal preg-
nancy deserves further investigation.
Conclusion
Based on this review, we can conclude that CA 125
values can be raised during pregnancy and both CA 15.3
and SCC levels generally remain below the cut-off values,
although higher levels are not uncommon. Inhibin B,
AMH and LDH levels are not elevated in maternal serum
during normal pregnancy. Despite its aforementioned
Han et al. BMC Medicine 2012, 10:86
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limitations, the reference table we have assembled pro-
vides a quick reference for gynecological tumor markers
during pregnancy.
Abbreviations
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